GlassScriptPhysician profile
Michelle Joseph
NPI 1326421389
$6,793.19
in general payments reported to CMS, 2019-2025
31 companies · $1,892 in 2025
The $1,892 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $220 · 2021: $858 · 2022: $1,043 · 2023: $1,415 · 2024: $1,241 · 2025: $1,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,547.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,123.44 | 2019-2025 | Tezspire, Airsupra, Bevespi Aerosphere |
| Glaxosmithkline, LLC. | $1,029.26 | 2020-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Optinose US, INC. | $598.39 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $571.67 | 2022-2025 | Dupixent |
| Grifols USA, LLC | $454.74 | 2022-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $442.20 | 2020-2025 | Cuvitru, Takhzyro |
| Csl Behring | $333.14 | 2021-2025 | Haegarda, Hizentra |
| Novartis Pharmaceuticals Corporation | $303.52 | 2022-2025 | |
| Ars Pharmaceuticals Operations, INC. | $274.15 | 2025 | Neffy |
| Genzyme Corporation | $268.13 | 2022-2025 | |
| Kaleo, INC. | $241.02 | 2021-2024 | Auvi-Q |
| Blueprint Medicines Corporation | $234.27 | 2023-2025 | Ayvakit |
| Amgen INC. | $153.63 | 2021-2025 | Tezspire |
| Pharming Healthcare, INC. | $99.79 | 2025 | Ruconest |
| Leo Pharma INC. | $68.14 | 2023-2025 | Adbry, Anzupgo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $64.33 | 2022-2023 | Opzelura |
| Octapharma USA, INC. | $64.15 | 2020-2021 | |
| Inspire Medical Systems, INC. | $62.48 | 2024-2025 | Inspire |
| Teva Pharmaceuticals USA, INC. | $60.54 | 2021 | |
| Hikma Pharmaceuticals USA | $59.09 | 2023-2024 | Ryaltris |
| Organon LLC | $41.94 | 2025 | |
| Olympus America INC. | $41.17 | 2024 | Rhino-Laryngo Videoscope |
| Aimmune Therapeutics, INC. | $38.64 | 2021-2022 | |
| Alk-Abello, INC | $32.17 | 2022 | |
| Apria Healthcare LLC | $25.43 | 2021 | |
| Lilly USA, LLC | $24.93 | 2024 | Ebglyss |
| Phadia US INC. | $22.55 | 2024 | Immunocap |
| Pfizer INC. | $15.58 | 2020 | |
| Paratek Pharmaceuticals, INC. | $15.20 | 2025 | Xhance, Nuzyra |
| Cycle Pharmaceuticals INC | $14.95 | 2025 | Sajazir |
| Kowa Pharmaceuticals America, INC. | $14.55 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.